The Impact of the Human Papilloma Virus in Pediatric Chronic Kidney Disease, Dialysis, and Transplant Patients
This trial is active, not recruiting.
|Conditions||chronic kidney disease, dialysis|
|Treatment||human papillomavirus vaccine|
|Collaborator||Merck Sharp & Dohme Corp.|
|Start date||November 2011|
|End date||December 2016|
|Trial size||72 participants|
|Trial identifier||NCT00767897, 0807-02|
The proposed study is a pilot study and a first step towards developing an optimized HPV vaccination strategy for girls who have CKD, or are on dialysis or have a kidney transplant.
Female participants from 9 years up to 18 years old.
- 9-18-year-old girls who have CKD stages 3 or 4 (Glomerular filtration rates 15-59 mL/min/1.73m2).
- 9-18-year-old girls who are on dialysis.
- 9-18-year-old girls who have had a functioning kidney transplant for longer than 6 months and are on the same immunosuppression regimen.
- Healthy 9-18-year-old girls
- Pregnancy, fever, allergy to any vaccine component, any immune disorder and any blood product received in the previous 6 months.
|Official title||The Impact of the Human Papilloma Virus in Pediatric Chronic Kidney Disease, Dialysis, and Transplant Patients|
|Principal investigator||Corina Nailescu, M.D.|
Call for more information